Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2012 | 03-2012 | 12-2011 | 09-2011 | 06-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,618 | -9,114 | -28,123 | -19,748 | -9,501 |
| Depreciation Amortization | 19 | 10 | 47 | 33 | 21 |
| Other Working Capital | -195 | -91 | 3,407 | 2,954 | 286 |
| Other Operating Activity | -1,555 | 646 | 1,847 | 1,564 | 1,092 |
| Operating Cash Flow | $-12,349 | $-8,549 | $-22,822 | $-15,197 | $-8,102 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,800 | -5,001 | -4,111 | -9,163 | -9,540 |
| PPE Investments | -3 | -2 | -57 | -48 | -34 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 324 |
| Investing Cash Flow | $-1,803 | $-5,003 | $-4,168 | $-9,211 | $-9,250 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | 0 | 33,830 | 33,830 | 32,149 |
| Financing Cash Flow | $0 | $0 | $33,830 | $33,830 | $32,149 |
| Beginning Cash Position | 35,252 | 35,252 | 28,412 | 28,412 | 28,412 |
| End Cash Position | 21,100 | 21,700 | 35,252 | 37,834 | 43,209 |
| Net Cash Flow | $-14,152 | $-13,552 | $6,840 | $9,422 | $14,797 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,349 | -8,549 | -22,822 | -15,197 | -8,102 |
| Capital Expenditure | -3 | -2 | -57 | -48 | -34 |
| Free Cash Flow | -12,352 | -8,551 | -22,879 | -15,245 | -8,136 |